Scalper1 News
Protena Corp. (PRTA) late Thursday reported clinical data showing that its new immunotherapy reduces a key protein linked to the disease, sending shares sharply higher in after-hours action. PRX002, a monoclonal antibody, safely reduced free serum alpha-synuclein, a potential disease-causing protein in Parkinson’s disease, by up to 96%, according to the early-stage trial. Protena is co-developing the treatment with Swiss drug giant Roche (RHHBY). Scalper1 News
Scalper1 News